Back to Journals » Biologics: Targets and Therapy » Volume 14

Evaluation of Therapeutic Drug Monitoring in the Clinical Management of Patients with Rheumatic Diseases: Data from a Retrospective Single-Center Cohort Study

Authors Pedersen L, Szecsi PB, Johansen PB, Bjerrum PJ

Received 12 May 2020

Accepted for publication 24 July 2020

Published 29 October 2020 Volume 2020:14 Pages 115—125

DOI https://doi.org/10.2147/BTT.S262511

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Dr Doris Benbrook


Lise Pedersen, 1 Pal Bela Szecsi, 1 Per Birger Johansen, 2 Poul Jannik Bjerrum 1

1Department of Clinical Biochemistry, University of Copenhagen, Holbæk Hospital, Holbæk, Denmark; 2Department of Rheumatology, University of Copenhagen, Holbæk Hospital, Holbæk, Denmark

Correspondence: Lise Pedersen Department of Clinical Biochemistry
University of Copenhagen, Holbæk Hospital, Holbæk Hospital, Smedelundsgade 60, Holbæk 4300, Denmark
Tel +45 59484403
Email liseped@regionsjaelland.dk

Purpose: Treatment of rheumatic diseases with tumor necrosis factor inhibitors leads to improved clinical outcomes. Therapeutic drug monitoring (TDM) may assist in guiding clinical decisions. This study investigates the impact of TDM on clinical outcome, decision-making and biologics cost expenditure.
Patients and Methods: In a retrospective observational study of 306 patients with rheumatic diseases treated with four different tumor necrosis factor inhibitors, drug levels and antidrug antibodies were measured over a period of one year. Primary outcomes were the clinicians’ response to each TDM result and the clinical outcome two years after TDM initiation. Outcomes were compared between the 111 TDM-guided patients and the 195 empirically guided patients.
Results: Treatment change occurred in 55% of the patients in the TDM group, but in only 38% in the empirically guided group. In the TDM group, 89 (79.5%) patients were in remission or had low disease activity after two years follow-up compared to 128 (65.6%) patients in the empirical group. The average cost of biologics per patient per year was lower in the TDM group than in the empirical group for patients receiving infliximab, adalimumab or etanercept at baseline but not for golimumab.
Conclusion: TDM-guided decision-making is useful in rheumatic patients receiving TNFi and may optimize therapeutic decisions, leading to a better control of disease activity. Proactive TDM may support decisions on dose tapering, resulting in lower drug consumption and biologics cost expenditure.

Keywords: infliximab, adalimumab, etanercept, golimumab, anti-drug antibodies

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]